Chimerix, Inc. (CMRX)
- American City Business Journals
As monkeypox spreads, Durham firm getting plenty of attention
A Durham company's smallpox treatment may be beneficial against monkeypox, according to the CDC. And it appears to be in high demand.
- Reuters
Chimerix gets up to $25.3 mln contract from Canada for smallpox drug
Chimerix Inc said on Friday it had been awarded a contract worth up to $25.3 million by Canada for its smallpox drug, likely to used to treat monkeypox as the viral infection spreads across the world. There have been more than 3,200 confirmed cases of monkeypox and one death reported in the last six weeks from 48 countries where it does not usually spread, according to the World Health Organization. The contract, awarded by the Public Health Agency of Canada, comes a day after Chimerix announced an order worth $9.3 million for the smallpox drug, Tembexa.
- GlobeNewswire
Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the
